Pre-Eclampsia Clinical Trial
Official title:
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
Verified date | July 2023 |
Source | University of New Mexico |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
NSAIDs, specifically cyclo-oxygenase (COX) inhibitors, are known to increase blood pressure over time in non-pregnant adults, but the effect of COX-inhibitors on blood pressure in the setting of preeclampsia have not been well studied. This study aims to assess the effect of avoiding COX-inhibitors on postpartum blood pressure control among women diagnosed with preeclampsia with severe features. Eligible women will be randomized to receive either acetaminophen or ibuprofen for postpartum pain control. Both agents are first line therapies for pain control although ibuprofen has better pain control than acetaminophen. The primary outcome will be duration of postpartum severe-range hypertension.
Status | Completed |
Enrollment | 100 |
Est. completion date | January 10, 2018 |
Est. primary completion date | November 7, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - ability to give informed consent - diagnosis of a "severe" hypertensive disorder of pregnancy: - preeclampsia with severe features - chronic hypertension with superimposed preeclampsia with severe features - HELLP syndrome: hemolysis, elevated liver function tests, low platelets - eclampsia - not yet delivered or less than 6 hours after delivery Exclusion Criteria: - current incarceration - serum creatinine > 1.0 mg/dL or suspicion of acute kidney injury - AST (aspartate aminotransferase) >200 unit/L - ALT (alanine aminotransferase) > 200 unit/L - known allergy or sensitivity to NSAIDs or acetaminophen - delivery > 6 hours prior to enrollment - chronic kidney disease - chronic liver disease - prior liver transplant - chronic infectious hepatitis - gastritis - gastro-esophageal reflux disease (GERD) - peptic ulcer disease - bleeding disorder - provider feels that participation is not in the best interest of the patient |
Country | Name | City | State |
---|---|---|---|
United States | University of New Mexico Health Sciences Center | Albuquerque | New Mexico |
Lead Sponsor | Collaborator |
---|---|
University of New Mexico |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of Severe-range Hypertension After Delivery | length of time from delivery to the last severe range blood pressure (160/110mm Hg) measured | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Length of Hospitalization | number of days from delivery until hospital discharge | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Mean Arterial Pressure Over the Entire Postpartum Hospitalization | computed mean arterial pressure using all measured blood pressures during postpartum hospitalization | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Mean Arterial Pressure, Stratified by Postpartum Day 1, 2, 3, Etc. | computed mean arterial pressure using all measured blood pressures during postpartum hospitalization, stratified by postpartum day (1, 2, 3, etc.) | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Mean Total Number of Severe Range Blood Pressure Measurements in Each Study Arm. | mean total number of severe range blood pressure (defined as SBP >160mmGh or DBP >110mmHg) measurements in each study arm | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Proportion of Study Participants in Each Study Arm Who Have Any Postpartum Severe Range BPs | Severe-range hypertension (defined as SBP > 160 mmHg or DBP >1100 mmHg) during postpartum stay | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Mean Maximum Measured Blood Pressure for Entire Postpartum Hospitalization (in mm Hg) | duration of postpartum hospitalization (approximately 3-7 days) | ||
Secondary | Proportion of Study Participants Requiring the Use of Scheduled Oral Antihypertensives at Discharge | duration of postpartum hospitalization (approximately 3-7 days) | ||
Secondary | Number of Scheduled Oral Antihypertensive Agents Required at Discharge | duration of postpartum hospitalization (approximately 3-7 days) | ||
Secondary | Need for Antihypertensives (Either Oral or Intravenous) for Acute Lowering of Blood Pressure | Proportion in each arm who required one or more doses of antihypertensive medication given for acute lowering of BP | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | The Proportion of Study Participants Requiring the Use of Intravenous Antihypertensives | The proportion of study participants in each study arm who require any IV antihypertensives to acutely lower blood pressure during their postpartum hospital stay. | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Mean Daily Pain Level, as Reported by Patient on Scale From 1-10, Stratified by Postpartum Day | Mean daily pain level, as reported by patient on scale from 1-10 (10 is most severe). | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Use of Opioid Analgesics, Measured in Morphine Milligram Equivalents Per Day, Stratified by Postpartum Day | duration of postpartum hospitalization (approximately 3-7 days) | ||
Secondary | Serum Creatinine Trend From Day of Delivery to Day of Discharge | duration of postpartum hospitalization (approximately 3-7 days) | ||
Secondary | Mean Drop in Hematocrit From Pre-delivery to the Nadir Prior to Discharge | Mean difference in hematocrit from pre-delivery to postpartum nadir prior to discharge | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Composite of Adverse Events | Adverse events include seizure, stroke, posterior reversible encephalopathy syndrome, repeat course of IV magnesium sulfate for seizure prophylaxis. | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Proportion of Study Participants in Each Study Arm With New Onset Postpartum Elevation of Liver Function Tests (AST, ALT) Above Twice the Normal Limit | AST: Aspartate aminotransferase; ALT: alanine aminotransferase | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Proportion of Study Participants in Each Study Arm With New Onset Postpartum Acute Kidney Injury | Acute kidney injury is defined as serum creatinine > 1.1mg/dL or double the baseline value | duration of postpartum hospitalization (approximately 3-7 days) | |
Secondary | Proportion of Study Participants in Each Study Arm With Delayed Postpartum Hemorrhage | Delayed postpartum hemorrhage is defined as > 1000 mL of blood loss occuring > 24 hours after delivery | duration of postpartum hospitalization (approximately 3-7 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03299777 -
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
|
N/A | |
Completed |
NCT03650790 -
C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies
|
N/A | |
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT03302260 -
Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT01911494 -
Community Level Interventions for Pre-eclampsia
|
N/A | |
Terminated |
NCT02025426 -
Phenylephrine Versus Ephedrine in Pre-eclampsia
|
Phase 4 | |
Completed |
NCT01352234 -
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
|
Phase 4 | |
Active, not recruiting |
NCT02031393 -
Establishing First Trimester Markers for the Identification of High Risk Twin
|
N/A | |
Terminated |
NCT00141310 -
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
|
Phase 2 | |
Completed |
NCT00157521 -
L-Arginine in Pre-Eclampsia
|
Phase 3 | |
Completed |
NCT04795154 -
Prenatal Yoga as Complementary Therapy of Preeclampsia
|
N/A | |
Completed |
NCT00004399 -
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
|
N/A | |
Completed |
NCT00005207 -
Renin and Prorenin in Pregnancy
|
N/A | |
Recruiting |
NCT04551807 -
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
|
Phase 3 | |
Terminated |
NCT04092829 -
Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer
|
N/A | |
Recruiting |
NCT06067906 -
Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients
|
N/A | |
Recruiting |
NCT06317467 -
Role of Anti-C1q Autoantibodies in Pregnancy
|
||
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Active, not recruiting |
NCT04484766 -
Preeclampsia Associated Vascular Aging
|
||
Completed |
NCT03509805 -
Sleep Apnea Syndrome in Obese Women During Pregnancy
|
N/A |